Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences
Portfolio Pulse from Benzinga Newsdesk
Marengo Therapeutics has entered a collaboration with Gilead Sciences to evaluate a combination therapy involving Marengo's STAR0602 and Gilead's Trodelvy in a Phase I/II clinical study. The study will focus on patients with metastatic TNBC or metastatic HR+/HER2- breast cancer.
September 13, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences is collaborating with Marengo Therapeutics to test a combination therapy involving Trodelvy in a new clinical study. This partnership could enhance Gilead's oncology portfolio if successful.
The collaboration with Marengo Therapeutics to test Trodelvy in combination with STAR0602 could lead to new treatment options in oncology, potentially boosting Gilead's product offerings and market position in the oncology sector.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80